Table 4.
Number of participants reporting expected reactions during two MDMA sessions and seven days following
| Placebo (n = 4) |
MDMA (n = 8) |
|
|---|---|---|
| Reactions during experimental sessions, no. (%)a | ||
| Anxiety | 1 (25.0) | 6 (75.0)b |
| Difficulty concentrating | 1 (25.0) | 5 (62.5)b |
| Fatigue | 1 (25.0) | 4 (50.0)b |
| Headache | 1 (25.0) | 4 (50.0)b |
| Lack of appetite | 1 (25.0) | 3 (37.5)c |
| Muscle tension | 1 (25.0) | 3 (37.5) |
| Restlessness | 1 (25.0) | 3 (37.5)b |
| Sensitivity to cold | 0 | 4 (50.0) |
| Dizziness | 1 (25.0) | 1 (12.5) |
| Low mood | 0 | 2 (28.6)b |
| Perspiration | 1 (25.0) | 1 (12.5) |
| Thirst | 0 | 2 (28.6) |
| Weakness | 1 (25.0) | 1 (12.5) |
| Drowsiness | 0 | 1 (12.5)b |
| Impaired gait/balance | 0 | 1 (12.5)b |
| Increased irritability | 0 | 1 (12.5)b |
| Jaw clenching, tight jaw | 0 | 1 (12.5) |
| Need more sleep | 0 | 1 (12.5)b |
| Ruminations | 0 | 1 (12.5) |
| None | 2 (50.0) | 0 |
| Top reactions during 7 days of contact, no. (%)a | ||
| Anxiety | 1 (25.0)b | 1 (12.5) |
| Difficulty concentrating | 0 | 4 (50.0) |
| Dizziness | 1 (25.0) | 0 |
| Drowsiness | 0 | 1 (12.5) |
| Fatigue | 2 (50.0) | 5 (62.5)e |
| Headache | 1 (25.0) | 5 (62.5)b,d |
| Increased irritability | 1 (25.0) | 1 (25.0) |
| Insomnia | 0 | 1 (12.5) |
| Jaw clenching, tight jaw | 1 (25.0) | 0 |
| Lack of appetite | 0 | 3 (37.5) |
| Low mood | 2 (50.0)c | 4 (50.0)c |
| Need more sleep | 2 (50.0) | 3 (37.5)b |
| Parasthesias | 0 | 1 (12.5) |
| Ruminations | 1 (25.0)b | 0 |
| Sensitivity to cold | 1 (25.0) | 0 |
| Thirst | 0 | 1 (12.5) |
| Weakness | 1 (25.0) | 1 (12.5) |
| None | 1 (25.0) | 0 |
Abbreviations: N, number of participants
aFrequency of subjects who reported an expected, spontaneously reported reaction collected during and 7 days following blinded experimental sessions 1 and 2
bOne moderate
cTwo moderate
dOne severe
eThree moderate